Dainippon Sumitomo expects hit from generic amlodipine
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma(DSP) expects the launch of a large number of generic amlodipine products in Japan in July to hit its branded version and top product Amlodin, sales of which it forecasts will slide by 10% to ¥57.0 billion ($530.2 million) this fiscal year.